Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans
Abstract
The aim of this study was to determine the cerebrospinal fluid (CSF) to plasma concentration ratio of atogepant. Healthy adult participants (N = 28) were enrolled into this phase 1, open-label study and received atogepant 60 mg once daily for 8 days. Steady-state atogepant concentrations were determined from CSF samples collected on Day 6 at 2 (n = 12) or 6 (n = 12) h postdose, and plasma samples were collected over 24 h after the Day 7 dose. Descriptive statistics for the atogepant CSF-to-plasma (CSF/plasma) ratio were calculated for each time point. The safety and tolerability profiles of atogepant were evaluated by clinical assessment of adverse events, physical examinations, 12-lead ECGs, laboratory tests, and vital sign measurements. The majority of adverse events were nonserious and mild in severity. Two participants discontinued the study. One due to asymptomatic moderately elevated liver enzymes and another due to mild confusional state/insomnia. Steady-state mean ± SD plasmatotal (bound + unbound) and CSF atogepant concentrations at 2 h were 652.54 ± 385.40 and 0.49 ± 0.78 ng/mL, and at 6 h were 163.14 ± 85.87 and 1.21 ± 1.14 ng/mL, respectively. The mean atogepant CSF/plasmatotal concentration ratio was 0.1% at 2 h and 0.7% at 6 h postdose. CSF/plasmaunbound concentration ratios at 2 and 6 h were 1.4% and 14.3%, respectively. Although the CNS penetration was low, considering atogepant's high affinity to CGRP receptors (Ki = 0.016 ng/mL) and a CIDV…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 28 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.